The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://lucykvrx999189.wssblogs.com/38952152/glp-3-retatrutide-a-comparative-analysis